Research programme: bispecific oncology antibodies - NovImmune

Drug Profile

Research programme: bispecific oncology antibodies - NovImmune

Alternative Names: NI 1601; NI 1701; NI 1801; NIBX-2101

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovImmune SA
  • Developer NovImmune SA; Shire
  • Class Antineoplastics; Bispecific antibodies; Blood coagulation factors
  • Mechanism of Action CD19 antigen inhibitors; CD47 antigen inhibitors; Factor IXa inhibitors; Factor X inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Haemophilia A; Non-Hodgkin's lymphoma
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Switzerland (Parenteral)
  • 18 Jul 2017 Preclinical trials in Haemophilia A in Switzerland (unspecified route)
  • 18 Jul 2017 Haemophilia A therapeutic licensed to Shire Worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top